1 week Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates Zacks

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?